Europe/Asia USA
Bachem AG Bachem Americas, Inc.
Hauptstrasse 144 3132 Kashiwa Street
4416 Bubendorf - Switzerland Torrance, CA 90505 - USA
Tel +41 61 935 2323 Tel +1 888 422 2436
Fax +41 61 935 2325 +1 888 4BACHEM
E-mail sales.ch@bachem.com +1 310 539 4171
  Fax +1 310 539 9428
  E-mail sales.us@bachem.com

L-NMMA ACETATE 250 mg/VIAL (CLINALFA® BASIC)

L-NMMA Acetate 250 mg/vial (Clinalfa basic)

U-1090, 4056509

 
Synonym

L-NMA

 
Sequence

H-Arg(Me)-OH acetate salt

 
To be used in approved clinical trials only
 
Active Substance

L-NMMA inhibits the synthesis of nitric oxide (NO) in a dose-dependent and enantio-specific fashion. Intravenous or intra-arterial injections of L-NMMA produce a powerful and prolonged vasoconstrictor effect, which can be reversed by L-Arg in a dose-dependent manner.

 
Literature References

A considerable number of publications on Clinalfa products used in clinical trials are available. The most important publications are listed here.
 

 
Note

This product is also available in research grade quality (non GMP)
 

E-3745

H-Arg(Me)-OH
(L-NMMA, Tilarginine, Targinine)